CMP
CCCC icon

Coston McIsaac & Partners’s C4 Therapeutics CCCC Stock Holding History

Coston McIsaac & Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23
Closed – – 741
2024
Q1 		$0 Buy
23
+4
+21% +$31 ﹤0.01% 722
2023
Q4 		$0 Buy
+19
New +$43 ﹤0.01% 722

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Coston McIsaac & Partners's CCCC Position: Q2 2024 in Review

Coston McIsaac & Partners sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 23 shares.

Coston McIsaac & Partners first reported a position in CCCC in Q4 2023 and held it in 2 quarters. The position peaked at $0 in Q1 2024. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

  • Coston McIsaac & Partners reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Coston McIsaac & Partners sold 23 C4 Therapeutics shares in Q2 2024.
  • Coston McIsaac & Partners first reported a position in C4 Therapeutics in Q4 2023 and held it in 2 quarters.
  • Coston McIsaac & Partners's C4 Therapeutics position peaked at $0 in Q1 2024.
  • 115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Coston McIsaac & Partners's 13F filing for Q2 2024, filed 31 Jul 2024.